• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Augmedix Inc. (Amendment)

    12/29/23 4:01:33 PM ET
    $AUGX
    Business Services
    Consumer Discretionary
    Get the next $AUGX alert in real time by email
    SC 13D/A 1 tm2333881d1_sc13da.htm SC 13D/A


    CUSIP NO.   05105P107
    13D Page 1 of 13

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13D

    (Amendment No. 4)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a)

     

    Augmedix, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    05105P107

    (CUSIP Number)

     

    Matthew C. Bonner

    c/o DCM

    2420 Sand Hill Road, Suite 200

    Menlo Park, CA 94025

    (650) 233-1400

     

    COPY TO:

    Christine Wichrowski, Esq.

    c/o Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

    550 Allerton Street, Redwood City, California 94063

    (650) 321-2400

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

      

    November 20, 2023 

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in the cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

    (Continued on following pages)

     

     

     


    CUSIP NO.   05105P107
    13D Page 2 of 13

     

    1

    NAME OF REPORTING
    SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     DCM VI, L.P. (“DCM VI”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 

    (a) ¨ (b) x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands




    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON
    WITH 
    5 SOLE VOTING POWER
    4,438,408 common shares (which includes 269,490 shares underlying warrants to purchase common stock held by DCM VI), except that DCM Investment Management VI, L.P. (“DGP VI”), the general partner of DCM VI, and DCM International VI, Ltd. (“UGP VI”), the general partner of DGP VI, may be deemed to have sole power to vote these shares, and F. Hurst Lin (“Lin”) and Matthew C. Bonner (“Bonner”), the directors of UGP VI, may be deemed to have shared power to vote these shares.  
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    4,438,408 common shares (which includes 269,490 shares underlying warrants to purchase common stock held by DCM VI), except that DGP VI, the general partner of DCM VI, and UGP VI, the general partner of DGP VI, may be deemed to have sole power to dispose of these shares, and Lin and Bonner, the directors of UGP VI, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,438,408
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.1%
    12 TYPE OF REPORTING PERSON* PN

      

     

     


    CUSIP NO.   05105P107
    13D Page 3 of 13

     

    1

    NAME OF REPORTING
    SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    DCM Investment Management VI, L.P. (“DGP VI”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 

    (a) ¨ (b) x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands




    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON
    WITH 
    5 SOLE VOTING POWER
    4,438,408 common shares (which includes 269,490 shares underlying warrants to purchase common stock held by DCM VI), except that DCM Investment Management VI, L.P. (“DGP VI”), the general partner of DCM VI, and DCM International VI, Ltd. (“UGP VI”), the general partner of DGP VI, may be deemed to have sole power to vote these shares, and F. Hurst Lin (“Lin”) and Matthew C. Bonner (“Bonner”), the directors of UGP VI, may be deemed to have shared power to vote these shares.  
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    4,438,408 common shares (which includes 269,490 shares underlying warrants to purchase common stock held by DCM VI) all of which are directly owned by DCM VI.  DGP VI, the general partner of DCM VI, may be deemed to have sole power to dispose of these shares, except that UGP VI, the general partner of DGP VI, may be deemed to have sole power to dispose of these shares, and Lin and Bonner, the directors of UGP VI, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,438,408
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.1%
    12 TYPE OF REPORTING PERSON* PN

     

     

     


    CUSIP NO.   05105P107
    13D Page 4 of 13

     

    1

    NAME OF REPORTING
    SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    DCM International VI, Ltd. (“UGP VI”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 

    (a) ¨ (b) x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands




    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON
    WITH 
    5 SOLE VOTING POWER
    4,438,408 common shares (which includes 269,490 shares underlying warrants to purchase common stock held by DCM VI) all of which are directly owned by DCM VI. UGP VI is the general partner of DGP VI, the general partner of DCM VI, and may be deemed to have sole power to vote these shares, except DGP VI, the general partner of DCM VI, may be deemed to have sole power to vote these shares, and Lin and Bonner, the directors of UGP VI, may be deemed to have shared power to vote these shares.  
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    4,438,408 common shares (which includes 269,490 shares underlying warrants to purchase common stock held by DCM VI) all of which are directly owned by DCM VI. UGP VI is the general partner of DGP VI, the general partner of DCM VI, and may be deemed to have sole power to dispose of these shares, except DGP VI, the general partner of DCM VI, may be deemed to have sole power to dispose of these shares, and Lin and Bonner, the directors of UGP VI, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,438,408
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.1%
    12 TYPE OF REPORTING PERSON* OO

      

     

     


    CUSIP NO.   05105P107
    13D Page 5 of 13

      

    1

    NAME OF REPORTING
    SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    A-Fund, L.P. (“A-Fund”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 

    (a) ¨ (b) x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands




    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON
    WITH 
    5 SOLE VOTING POWER
    20,007 common shares, except that A-Fund Investment Management, L.P. (“A-Fund DGP”), the general partner of A-Fund, and A-Fund International, Ltd. (“A-Fund UGP”), the general partner of A-Fund DGP, may be deemed to have sole power to vote these shares, and Lin and Bonner, the directors of A-Fund UGP, may be deemed to have shared power to vote these shares.  
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    20,007 common shares, except that A-Fund DGP, the general partner of A-Fund, and A-Fund UGP, the general partner of A-Fund DGP, may be deemed to have sole power to dispose of these shares, and Lin and Bonner, the directors of A-Fund UGP, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 20,007
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.1%
    12 TYPE OF REPORTING PERSON* PN

      

     

     

     


    CUSIP NO.   05105P107
    13D Page 6 of 13

      

    1

    NAME OF REPORTING
    SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    A-Fund Investment Management, L.P. (“A-Fund DGP”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 

    (a) ¨ (b) x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands




    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON
    WITH 
    5 SOLE VOTING POWER
    20,007 common shares all of which are directly owned by A-Fund.  A-Fund DGP, the general partner of A-Fund, may be deemed to have sole power to vote these shares, except that A-Fund UGP, the general partner of A-Fund DGP, may be deemed to have sole power to vote these shares, and Lin and Bonner, the directors of A-Fund UGP, may be deemed to have shared power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    20,007 common shares all of which are directly owned by A-Fund.  A-Fund DGP, the general partner of A-Fund, may be deemed to have sole power to dispose of these shares, except that A-Fund UGP, the general partner of A-Fund DGP, may be deemed to have sole power to dispose of these shares, and Lin and Bonner, the directors of A-Fund UGP, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 20,007
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.1%
    12 TYPE OF REPORTING PERSON* PN

      

     

     


    CUSIP NO.   05105P107
    13D Page 7 of 13

     

    1

    NAME OF REPORTING
    SS OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    A-Fund International, Ltd. (“A-Fund UGP”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 

    (a) ¨ (b) x

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands




    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON
    WITH 
    5 SOLE VOTING POWER
    20,007 common shares all of which are directly owned by A-Fund. A-Fund UGP is the general partner of A-Fund DGP, the general partner of A-Fund, and may be deemed to have sole power to vote these shares, except A-Fund DGP, the general partner of A-Fund, may be deemed to have sole power to vote these shares, and Lin and Bonner, the directors of A-Fund UGP, may be deemed to have shared power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    20,007 common shares all of which are directly owned by A-Fund. A-Fund UGP is the general partner of A-Fund DGP, the general partner of A-Fund, and may be deemed to have sole power to dispose of these shares, except A-Fund DGP, the general partner of A-Fund, may be deemed to have sole power to dispose of these shares, and Lin and Bonner, the directors of A-Fund UGP, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 20,007
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.1%
    12 TYPE OF REPORTING PERSON* OO

     

     

     


    CUSIP NO.   05105P107
    13D Page 8 of 13

     

    1 NAME OF REPORTING PERSON

    F. Hurst Lin (“Lin”)

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a) ¨    (b) x
    3 SEC USE ONLY  
    4 CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen




    NUMBER OF

     SHARES 

    BENEFICIALLY

     OWNED BY EACH

     REPORTING

     PERSON

     WITH

     

    5 SOLE VOTING POWER
    0 shares.
    6 SHARED VOTING POWER
    4,458,415 common shares of which 4,438,408 (which includes 269,490 shares underlying warrants to purchase common stock held by DCM VI) are directly owned by DCM VI and 20,007 are owned directly by A-Fund. Lin is a director of each of UGP VI, the general partner of DGP VI, which is the general partner of DCM VI, and A-Fund UGP, the general partner of A-Fund DGP, which is the general partner of A-Fund, and may be deemed to have shared power to vote these shares.
    7 SOLE DISPOSITIVE POWER
    0 shares.
    8 SHARED DISPOSITIVE POWER
    4,458,415 common shares of which 4,438,408 (which includes 269,490 shares underlying warrants to purchase common stock held by DCM VI) are directly owned by DCM VI and 20,007 are owned directly by A-Fund. Lin is a director of each of UGP VI, the general partner of DGP VI, which is the general partner of DCM VI, and A-Fund UGP, the general partner of A-Fund DGP, which is the general partner of A-Fund, and may be deemed to have shared power to dispose of these shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,458,415
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.1%
    12 TYPE OF REPORTING PERSON* IN

     

     

     


    CUSIP NO.   05105P107
    13D Page 9 of 13

      

    1 NAME OF REPORTING PERSON Matthew C. Bonner (“Bonner”)
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   (a) ¨    (b) x
    3 SEC USE ONLY  
    4 CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen




    NUMBER OF

     SHARES 

    BENEFICIALLY

     OWNED BY EACH

     REPORTING

     PERSON

     WITH

     

    5 SOLE VOTING POWER
    0 shares.
    6 SHARED VOTING POWER
    4,458,415 common shares of which 4,438,408 (which includes 269,490 shares underlying warrants to purchase common stock held by DCM VI) are directly owned by DCM VI and 20,007 are owned directly by A-Fund. Bonner is a director of each of UGP VI, the general partner of DGP VI, which is the general partner of DCM VI, and A-Fund UGP, the general partner of A-Fund DGP, which is the general partner of A-Fund, and may be deemed to have shared power to vote these shares.
    7 SOLE DISPOSITIVE POWER
    0 shares.
    8 SHARED DISPOSITIVE POWER
    4,458,415 common shares of which 4,438,408 (which includes 269,490 shares underlying warrants to purchase common stock held by DCM VI) are directly owned by DCM VI and 20,007 are owned directly by A-Fund. Bonner is a director of each of UGP VI, the general partner of DGP VI, which is the general partner of DCM VI, and A-Fund UGP, the general partner of A-Fund DGP, which is the general partner of A-Fund, and may be deemed to have shared power to dispose of these shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,458,415
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.1%
    12 TYPE OF REPORTING PERSON* IN

     

     

     

     


    CUSIP NO.   05105P107
    13D Page 10 of 13

     

    ITEM 1.SECURITY AND ISSUER.

     

    This Amendment No. 4 supplements and amends the Schedule 13D that was originally filed on October 5, 2020 as amended by Amendment No. 1 filed on October 28, 2021, Amendment No. 2 filed on January 26, 2023 and Amendment No. 3 filed on November 3, 2023 (the “Original Schedule 13D”). This Amendment No. 4 relates to the common stock, par value $0.0001 per share (the “Common Stock”), of Augmedix, Inc., a Delaware corporation (the “Company”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 4 have the meanings ascribed to them in the Original Schedule 13D. The Company’s principal executive offices are located at 1161 Mission Street, Suite LL, San Francisco, California, 94103.

     

     

    ITEM 5.INTEREST IN SECURITIES OF THE ISSUER.

     

    Items 5(a) and 5(b) of the Original Schedule 13D are hereby amended and restated in their entirety as follows:

     

    (a,b) Regarding aggregate beneficial ownership, see Row 9 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 5 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 6 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 8 of the cover page of each Reporting Person. Persons may be deemed to constitute a “group” for purposes of Section 13(d)(3) of the Act. The filing of this Statement shall not be construed as an admission that the Reporting Persons are a group, or have agreed to act as a group. Each Reporting Person expressly disclaims beneficial ownership in the securities reported herein except to the extent such Reporting Person actually exercises voting or dispositive power with respect to such securities. The percentage listed in Row 11 for each Reporting Person was calculated based upon 48,555,216 outstanding shares of common stock outstanding as disclosed by the Company in its Prospectus Supplement filed on November 17, 2023.

     

     

     

     


    CUSIP NO.   05105P107
    13D Page 11 of 13

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated as of: November 20, 2023

     

      DCM VI, L.P.
         
      By: DCM Investment Management VI, L.P.
      Its General Partner
         
      By:  DCM International VI, Ltd.
      Its General Partner
         
      By: /s/ Matthew C. Bonner
        Matthew C. Bonner, Attorney-In-Fact*
         
      DCM INVESTMENT MANAGEMENT VI, L.P.
         
      By:  DCM International VI, Ltd.
      Its General Partner
         
      By: /s/ Matthew C. Bonner
        Matthew C. Bonner, Attorney-In-Fact*
         
      DCM International VI, Ltd.
         
      By: /s/ Matthew C. Bonner
        Matthew C. Bonner, Attorney-In-Fact*
         
      A-FUND, L.P.
         
      By:  A-FUND INVESTMENT MANAGEMENT, L.P.
      Its General Partner
         
      By:  A-FUND INTERNATIONAL, LTD.
      Its General Partner
         
      By: /s/ Matthew C. Bonner
        Matthew C. Bonner, Attorney-In-Fact*
         
      A-FUND INVESTMENT MANAGEMENT, L.P.
         
      By:  A-FUND INTERNATIONAL, LTD.
      Its General Partner
         
      By: /s/ Matthew C. Bonner
        Matthew C. Bonner, Attorney-In-Fact*

     

     

     


    CUSIP NO.   05105P107
    13D Page 12 of 13

     

     

      A-FUND INTERNATIONAL, LTD.
         
         
      By: /s/ Matthew C. Bonner
        Matthew C. Bonner, Attorney-In-Fact*
         
      F. HURST LIN
       
      /s/ F. Hurst Lin
      Matthew C. Bonner, Attorney-In-Fact*
         
      MATTHEW C. BONNER
       
      /s/ Matthew C. Bonner
      Matthew C. Bonner

     

    * Signed pursuant to a Power of Attorney already on file with the appropriate agencies.

     

     

     

     


    CUSIP NO.   05105P107
    13D Page 13 of 13

     

     

    exhibit A

     

    Agreement of Joint Filing

     

     

    The Reporting Persons agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Augmedix, Inc. shall be filed on behalf of each of the Reporting Persons. Note that copies of the applicable Agreement of Joint Filing are already on file with the appropriate agencies.

     

     

     

     

     

     

    Get the next $AUGX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AUGX

    DatePrice TargetRatingAnalyst
    7/22/2024Buy → Hold
    Lake Street
    7/22/2024$3.00 → $2.35Buy → Neutral
    B. Riley Securities
    5/14/2024$5.00Buy → Hold
    Maxim Group
    5/14/2024$5.00 → $1.50Outperform → In-line
    Evercore ISI
    4/3/2024$5.50Buy
    B. Riley Securities
    12/15/2023$6.00In-line
    Evercore ISI
    3/7/2022$6.00Buy
    Lake Street
    1/21/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $AUGX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Augmedix Inc.

      15-12G - Augmedix, Inc. (0001769804) (Filer)

      10/15/24 9:32:28 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Augmedix Inc.

      EFFECT - Augmedix, Inc. (0001769804) (Filer)

      10/4/24 12:15:04 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Augmedix Inc.

      EFFECT - Augmedix, Inc. (0001769804) (Filer)

      10/4/24 12:15:02 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Augmedix downgraded by Lake Street

      Lake Street downgraded Augmedix from Buy to Hold

      7/22/24 8:25:03 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Augmedix from Buy to Neutral and set a new price target of $2.35 from $3.00 previously

      7/22/24 8:02:58 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix downgraded by Maxim Group with a new price target

      Maxim Group downgraded Augmedix from Buy to Hold and set a new price target of $5.00

      5/14/24 8:17:17 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Commure Completes Merger with Augmedix

      SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

      10/2/24 8:23:42 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

      SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. "We believe we are approaching the proposed combination with Commure, Inc. from a position of strength, with consistent double-digit revenue growth and improving gross margins," commented Manny Krakaris, Augmedix CEO. "Together, we believe we will be well-positioned to continue to streamline the medical documentation ecosystem with a growing base of health system customers, solid partners, and proven solutions. As part of Commure, we expect to scale our ambient documentation solu

      8/12/24 4:01:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

      8/6/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ginocchio Paul bought $48,500 worth of shares (10,000 units at $4.85), increasing direct ownership by 8% to 128,000 units (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      11/27/23 7:00:06 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Redmile Group, Llc bought $6,000,000 worth of shares (1,500,000 units at $4.00) (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      11/22/23 4:15:24 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc returned $75,402,504 worth of shares to the company (32,086,172 units at $2.35) (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 5:01:03 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form 4 filed by Director Faulkner Robert C.

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 5:00:14 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Director Febbo William J returned $382,070 worth of shares to the company (162,583 units at $2.35), closing all direct ownership in the company (SEC Form 4)

      4 - Augmedix, Inc. (0001769804) (Issuer)

      10/4/24 1:17:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Augmedix to Join Forces with Commure

      SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction, and Augmedix will become a wholly-owned subsidiary of Commure. The purchase price represents a premium of approximately 169% over the volume weighted average price

      7/19/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer

      SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient artificial intelligence (AI) medical documentation and data solutions, today announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. "Welcoming Dr. Stinard to join Augmedix in this new role is an exciting step forward in implementing advanced AI technolog

      5/29/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

      SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies' combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products. "We are thrilled to join forces with SADA, to partner with an organization that has a nationwide reach to health systems, and also to leverage their prowess in frontier cloud infr

      4/4/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Financials

    Live finance-specific insights

    See more
    • Commure Completes Merger with Augmedix

      SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

      10/2/24 8:23:42 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

      8/6/24 7:00:00 AM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

      SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. "Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins," commented Manny Krakaris, Augmedix CEO. "We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products." "We a

      5/13/24 4:03:00 PM ET
      $AUGX
      Business Services
      Consumer Discretionary

    $AUGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

      SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

      10/4/24 5:00:14 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by Augmedix Inc.

      SC 13G - Augmedix, Inc. (0001769804) (Subject)

      7/29/24 5:23:20 PM ET
      $AUGX
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

      SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

      7/19/24 7:45:47 PM ET
      $AUGX
      Business Services
      Consumer Discretionary